The short version of BDNF expression fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-19 and is reviewed periodically as new material appears.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Eq. 2 The SIMS-SS age equation in years before present Where, Ci is the intrinsic concentration of water, Cs is the saturation concentration, dC/dx is the diffusion coefficient for depth x=0, k is derived from a family of Crank's theoretical diffusion curves, and
Analogues of flmodafinil include modafinil, armodafinil ((R)-modafinil), esmodafinil ((S)-modafinil), adrafinil (CRL-40,028; N-hydroxymodafinil), fladrafinil (CRL-40,941; bisfluoroadrafinil), and CE-123, among others.
== Nutritional sources == Myo-inositol is naturally present in a variety of foods, although tables of food composition do not always distinguish between lecithin, the relatively bioavailable lipid form and the biounavailable phytate/phosphate form. Foods containing the highest concentrations of myo-inositol and its compounds include fruits, beans, grains, and nuts. Fruits in particular, especially oranges and cantaloupe, contain the highest amounts of myo-inositol. It is also present in beans, nuts, and grains, however, these contain large amounts of myo-inositol in the phytate form, which is not bioavailable without transformation by phytase enzymes. Bacillus subtilis, the microorganism which produces the fermented food natto, produces phytase enzymes that may convert phytic acid to a more bioavailable form of inositol polyphosphate in the gut. Additionally, Bacteroides species in the gut secrete vesicles containing an active enzyme which converts the phytate molecule into bioavailable phosphorus and inositol polyphosphate, which is an important signaling molecule in the human body. Myo-inositol can also be found as an ingredient in energy drinks, either in conjunction with or as a substitute for glucose. In humans, myo-inositol is naturally made from glucose-6-phosphate through enzymatic dephosphorylation.
Sources: en.wikipedia.org
==== Grand Encampment ==== In 1914, the Grand Master of the Grand Encampment of the Knights Templar in the United States, Joseph K. Orr, visited Havana, where he found 50 members of the fraternity. In 1921, he authorized the formation of a Commandery and issued dispensation to the Havana Commandery U. D., K. T., where Walter M. Daniels was made Commander. General George M. Moulton made an inspection of the ranks, and the Havana Commandery received its charter on April 27, 1922. By 1951, they had 91 members.
In relation to the significance of the event(s) on career choice, when merging the categories ‘probably chosen career regardless’ with ‘possibly chosen career regardless’, and ‘unlikely chosen career regardless’ with ‘not considered career otherwise’, there is a slight majority in relation to the former. There are no significant differences in relation to demographic factors. In relation to whether one or more psychologically wounding experiences led to the choice of a career as a therapist, there is a significant difference within designation, gender, grouping gender and ethnicity, and, grouping gender and age. There are no significant differences within approach, ethnicity or age. The majority of the wounds were caused by events experienced directly by the respondents (65%) as opposed to indirectly or both. Within demographic factors, the causes of the wounding experiences leading to career choice are not statistically significant. The exact causes of the wounds vary enormously. The main categories are abuse, family life as a child, mental ill-health (own), social, family life as an adult, bereavement, mental ill-health (others), life-threatening, physical ill-health (others), physical ill-health (own), and, other. There are many implications for the future of the therapeutic world, focusing mainly on supervision and training. The largest prevalence study on lived experience within the mental health field by Victor et al.
== Facilities and subsidiaries == The BMC is headquartered in Lobatse. Its facilities consist of an integrated complex which includes an abattoir, canning, tanning and by-products plants. A throughput of 8000 cattle and 500 small stock are handled on a daily basis. The BMC also operates two branch abattoirs, one in Maun and the other in Francistown, with respective capacities of 100 cattle per day and 400 cattle and 150 small stock per day. Along with its core business, the BMC owns transport companies in Botswana. On an international scale, it also owns marketing subsidiaries in European countries including the United Kingdom, Germany and the Netherlands, and cold storage facilities in the UK and South Africa. It also owns an insurance company in the Cayman Islands.
==== III. Microbubble Loading Inside Liposome ==== Another novel acoustically responsive microbubble system is the direct encapsulation of microbubbles inside of a liposome. Theses systems circulate longer in the body than microbubbles alone do, as this packaging method prevents the microbubble from dissolving in the blood stream. Hydrophilic drugs persist in the aqueous media inside the liposome, while hydrophobic drugs congregate in the lipid bilayer. It has been shown in vitro that macrophages do not engulf these particles.
Sources: en.wikipedia.org
== P == Paal–Knorr pyrrole synthesis Paal–Knorr synthesis Paneth technique Passerini reaction Paternò–Büchi reaction Pauson–Khand reaction Payne rearrangement Pechmann condensation Pechmann pyrazole synthesis Pellizzari reaction Pelouze synthesis Peptide synthesis Perkin alicyclic synthesis Perkin reaction Perkin rearrangement Perkow reaction Petasis reaction Petasis reagent Peterson olefination Peterson reaction Petrenko-Kritschenko piperidone synthesis Pfau–Plattner azulene synthesis Pfitzinger reaction Pfitzner–Moffatt oxidation Phosphonium coupling Photosynthesis Piancatelli rearrangement Pictet–Gams isoquinoline synthesis Pictet–Hubert reaction Pictet–Spengler tetrahydroisoquinoline synthesis Pictet–Spengler reaction Piloty–Robinson pyrrole synthesis Pinacol coupling reaction Pinacol rearrangement Pinner amidine synthesis Pinner method for ortho esters Pinner reaction Pinner triazine synthesis Pinnick oxidation Piria reaction Polonovski reaction Pomeranz–Fritsch reaction Ponzio reaction Prato reaction Prelog strain Prevost reaction Prileschajew reaction Prilezhaev reaction Prins reaction Prinzbach synthesis Protecting group Pschorr reaction Pummerer rearrangement Purdie methylation, Irvine–Purdie methylation
SR-17018 was subsequently assessed in rhesus monkeys and produced analgesic effects in this species that could be reversed by the MOR antagonist naltrexone, whereas respiratory depression could not be assessed due to solubility limitations. While conventional opioids like morphine produced robust itch-scratching behaviors, SR-17018 and buprenorphine only caused mild such effects, suggesting low-efficacy MOR activation. Although SR-17018 was reported to produce very little respiratory depression in mice, a subsequent study using oral administration instead of intraperitoneal administration, with the former having greater bioavailability, unexpectedly found significant respiratory depression with the drug. SR-17018 produced less analgesic tolerance than other MOR agonists in mice. Whereas morphine and oxycodone produced robust tolerance in the hot plate test with chronic administration, SR-17018 produced no or only slight tolerance in this assay depending on the dosage. In addition, whereas morphine caused MOR desensitization in the periaqueductal gray (PAG), a key brain area implicated in the analgesic effects of MOR agonists, SR-17018 produced no desensitization. Similarly, unlike morphine, SR-17018 did not cause upregulation of forskolin-stimulated cAMP accumulation in striatal membranes. Despite the preceding findings however, discontinuation of both morphine and SR-17018 caused withdrawal symptoms in mice, though withdrawal symptoms were lower with SR-17018 compared to morphine.
==== Liposomal ==== To improve the tolerability of amphotericin and reduce toxicity, researchers developed several lipid formulations. Liposomal formulations have been found to have less renal toxicity than deoxycholate, and fewer infusion-related reactions. They are more expensive than amphotericin B deoxycholate. AmBisome (liposomal amphotericin B; LAMB) is a liposomal formulation of amphotericin B for injection and consists of a mixture of phosphatidylcholine, cholesterol and distearoyl phosphatidylglycerol that in aqueous media spontaneously arrange into unilamellar vesicles that contain amphotericin B. It was developed by NeXstar Pharmaceuticals (acquired by Gilead Sciences in 1999). It was approved by the United States Food and Drug Administration (FDA) in 1997. It is marketed by Gilead in Europe and licensed to Astellas Pharma (formerly Fujisawa Pharmaceuticals) for marketing in the US, and Sumitomo Pharmaceuticals in Japan.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.